Emilda Thompson
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
Molife L, Pelling K, Temple G, Heath C, Wheatley D, Oommen N, Thompson E, Jenkins P, Hickish T, Pedley I, O'Sullivan J, Olmos D, Fong P, Lumsden G, Bloomfield D, Karavasilis V, Jones R, Omlin A, de Bono J. Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncol 2014; 10:219-31.
Feb 1, 2014Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
Feb 1, 2014Future Oncol 2014; 10:219-31
Molife L Rhoda, Pelling Katy, Temple Graham, Heath Catherine, Wheatley Duncan, Oommen Nikhil, Thompson Emilda, Jenkins Peter, Hickish Tamas, Pedley Ian, O'Sullivan Joe M, Olmos David, Fong Peter C, Lumsden Graeme, Bloomfield David, Karavasilis Vasilios, Jones Rob J, Omlin Aurelius, de Bono Johann S
Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms
Omlin A, Attard G, Parker C, Thompson E, Maier G, Ferraldeschi R, Olmos D, Bianchini D, Sandhu S, Mulick Cassidy A, Mukherji D, Pezaro C, de Bono J. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol 2013; 64:300-6.
Jan 4, 2013Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms
Jan 4, 2013Eur Urol 2013; 64:300-6
Omlin Aurelius, Attard Gerhardt, Parker Chris, Thompson Emilda, Maier Gal, Ferraldeschi Roberta, Olmos David, Bianchini Diletta, Sandhu Shahneen, Mulick Cassidy Amy, Mukherji Deborah, Pezaro Carmel, de Bono Johann